Real-world post-2020 first-line maintenance treatment patterns in patients with advanced ovarian cancer in the US.

IF 2.6 4区医学 Q2 ONCOLOGY

Future oncology Pub Date : 2025-08-01 Epub Date: 2025-07-14 DOI:10.1080/14796694.2025.2526273

Dana M Chase, Linda Kalilani, Maureen A Cooney, Zsofia Kiss, Amanda K Golembesky, Monica Kobayashi, Megha Dayma, Elif Coskuncay, Jeanne M Schilder

{"title":"Real-world post-2020 first-line maintenance treatment patterns in patients with advanced ovarian cancer in the US.","authors":"Dana M Chase, Linda Kalilani, Maureen A Cooney, Zsofia Kiss, Amanda K Golembesky, Monica Kobayashi, Megha Dayma, Elif Coskuncay, Jeanne M Schilder","doi":"10.1080/14796694.2025.2526273","DOIUrl":null,"url":null,"abstract":"Aims: To describe first-line maintenance (1LM) treatment patterns since 1 January 2020, for real-world patients with newly diagnosed advanced ovarian cancer (aOC).Patients & methods: This retrospective study used a US-nationwide electronic health record-derived deidentified database. Eligible patients were aged ≥ 18 years with stage III/IV epithelial OC and initiated first-line platinum-based chemotherapy±bevacizumab (index; 01Jan2020-28Feb2023). Baseline characteristics and 1LM treatment patterns were summarized overall and by BRCA status.Results: Among 599 eligible patients (median [interquartile range] age, 67 [59-74] years; 59.8% White; 50.3% stage III disease), 15.5% had BRCA-mutated (BRCAm), 72.3% BRCA wild-type (BRCAwt), and 12.2% unknown BRCA status. Overall, 289 patients (48.2%) received 1LM therapy (poly(ADP-ribose) polymerase inhibitor [PARPi] monotherapy, 23.4%; bevacizumab monotherapy, 14.7%; bevacizumab+PARPi, 7.8%; other therapies, 2.3%). PARPi monotherapy was most common among patients with BRCAm (47.3%) versus BRCAwt (21.7%) or BRCA-unknown (2.7%) status. The same was true for 1LM bevacizumab+PARPi (BRCAm, 16.1%; BRCAwt, 7.4%; BRCA-unknown, 0%). Bevacizumab monotherapy was most common among patients with BRCAwt (18.7%) versus BRCAm (3.2%) or BRCA-unknown (5.5%) status.Conclusions: Fewer than half of included patients with aOC received 1LM treatment in the real-world setting. More work is needed to understand reasons underlying real-world 1LM treatment choice for patients with aOC.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2495-2503"},"PeriodicalIF":2.6000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12330229/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14796694.2025.2526273","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/14 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aims: To describe first-line maintenance (1LM) treatment patterns since 1 January 2020, for real-world patients with newly diagnosed advanced ovarian cancer (aOC).

Patients & methods: This retrospective study used a US-nationwide electronic health record-derived deidentified database. Eligible patients were aged ≥ 18 years with stage III/IV epithelial OC and initiated first-line platinum-based chemotherapy±bevacizumab (index; 01Jan2020-28Feb2023). Baseline characteristics and 1LM treatment patterns were summarized overall and by BRCA status.

Results: Among 599 eligible patients (median [interquartile range] age, 67 [59-74] years; 59.8% White; 50.3% stage III disease), 15.5% had BRCA-mutated (BRCAm), 72.3% BRCA wild-type (BRCAwt), and 12.2% unknown BRCA status. Overall, 289 patients (48.2%) received 1LM therapy (poly(ADP-ribose) polymerase inhibitor [PARPi] monotherapy, 23.4%; bevacizumab monotherapy, 14.7%; bevacizumab+PARPi, 7.8%; other therapies, 2.3%). PARPi monotherapy was most common among patients with BRCAm (47.3%) versus BRCAwt (21.7%) or BRCA-unknown (2.7%) status. The same was true for 1LM bevacizumab+PARPi (BRCAm, 16.1%; BRCAwt, 7.4%; BRCA-unknown, 0%). Bevacizumab monotherapy was most common among patients with BRCAwt (18.7%) versus BRCAm (3.2%) or BRCA-unknown (5.5%) status.

Conclusions: Fewer than half of included patients with aOC received 1LM treatment in the real-world setting. More work is needed to understand reasons underlying real-world 1LM treatment choice for patients with aOC.

Abstract Image

查看原文本刊更多论文

美国晚期卵巢癌患者2020年后一线维持治疗模式的现实世界

目的：描述自2020年1月1日以来新诊断的晚期卵巢癌（aOC）患者的一线维持（1LM）治疗模式。患者和方法：本回顾性研究使用美国全国电子健康记录衍生的未识别数据库。符合条件的患者年龄≥18岁，患有III/IV期上皮性OC，并开始了一线铂基化疗±贝伐单抗(指数；01 jan2020-28feb2023)。根据BRCA状态对基线特征和1LM治疗模式进行总体总结。结果：在599例符合条件的患者中(年龄中位数[四分位数间距]为67[59-74]岁；59.8%的白人;50.3%为III期疾病)，15.5%为BRCA突变（BRCAm）， 72.3%为BRCA野生型（BRCAwt）， 12.2%为未知BRCA状态。总体而言，289例患者（48.2%）接受了1LM治疗(聚（adp -核糖）聚合酶抑制剂[PARPi]单药治疗，23.4%；贝伐单抗单药治疗，14.7%；贝伐单抗+ PARPi, 7.8%;其他治疗，2.3%)。PARPi单药治疗在BRCAm（47.3%）和brcat（21.7%）或brca未知（2.7%）状态的患者中最常见。1LM贝伐单抗+PARPi也是如此(BRCAm, 16.1%；BRCAwt, 7.4%;BRCA-unknown, 0%)。贝伐单抗单药治疗在brcat（18.7%）和BRCAm（3.2%）或brca未知（5.5%）状态的患者中最常见。结论：在现实世界中，只有不到一半的aOC患者接受了1LM治疗。需要做更多的工作来了解aOC患者选择1LM治疗的真实原因。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Future oncology ONCOLOGY-

CiteScore

5.40

自引率

3.00%

发文量

335

审稿时长

4-8 weeks

期刊介绍： Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community. The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.